Home / Congress Presentations / C3G and IC-MPGN / American Society of Nephrology (ASN) Kidney Week 2024
Landing
American Society of Nephrology (ASN) Kidney Week 2024
Pegcetacoplan for post-transplant recurrent C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis in NOBLE: 52-week patient evolution
Long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis: The long-term VALE extension study
VALIANT: Phase 3 Trial of Pegcetacoplan for Patients With Native or Post-Transplant Recurrent C3G or Primary IC-MPGN
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.